GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (LTS:0A8L) » Definitions » Cyclically Adjusted Price-to-FCF

OpGen (LTS:0A8L) Cyclically Adjusted Price-to-FCF : (As of May. 21, 2024)


View and export this data going back to 2021. Start your Free Trial

What is OpGen Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


OpGen Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for OpGen's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen Cyclically Adjusted Price-to-FCF Chart

OpGen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OpGen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OpGen's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, OpGen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OpGen's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OpGen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where OpGen's Cyclically Adjusted Price-to-FCF falls into.



OpGen Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

OpGen's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, OpGen's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-3.451/129.8595*129.8595
=-3.451

Current CPI (Sep. 2023) = 129.8595.

OpGen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 0.000 98.326 0.000
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 -15,700.000 99.621 -20,465.485
201506 -26,181.818 100.684 -33,768.634
201509 -59,581.818 100.392 -77,070.918
201512 -27,516.667 99.792 -35,807.342
201603 -31,650.000 100.470 -40,908.100
201606 -46,141.667 101.688 -58,924.631
201609 -19,047.368 101.861 -24,282.912
201612 -20,090.909 101.863 -25,612.863
201703 -17,948.000 102.862 -22,658.647
201706 -12,400.000 103.349 -15,580.763
201709 -3,509.000 104.136 -4,375.804
201712 -3,236.000 104.011 -4,040.197
201803 -2,232.000 105.290 -2,752.852
201806 -3,327.000 106.317 -4,063.728
201809 -1,409.000 106.507 -1,717.939
201812 -1,349.000 105.998 -1,652.679
201903 -1,497.000 107.251 -1,812.576
201906 -713.500 108.070 -857.363
201909 -570.000 108.329 -683.286
201912 -121.714 108.420 -145.782
202003 -63.405 108.902 -75.607
202006 -89.455 108.767 -106.802
202009 -75.271 109.815 -89.010
202012 -66.660 109.897 -78.769
202103 -39.571 111.754 -45.982
202106 -44.319 114.631 -50.207
202109 -27.398 115.734 -30.742
202112 -19.448 117.630 -21.470
202203 -21.897 121.301 -23.442
202206 -28.777 125.017 -29.892
202209 -20.408 125.227 -21.163
202212 -16.114 125.222 -16.711
202303 -11.557 127.348 -11.785
202306 -8.192 128.729 -8.264
202309 -3.451 129.860 -3.451

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OpGen  (LTS:0A8L) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


OpGen Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of OpGen's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


OpGen (LTS:0A8L) Business Description

Traded in Other Exchanges
Address
9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.

OpGen (LTS:0A8L) Headlines

No Headlines